Eurosurv. Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025

[tetano]

• Hanne-Dorthe Emborg¹ , Palle Valentiner-Branth¹ , Ramona Trebbien² , Amanda Bolt Botnen² , Tyra Grove Krause³ , Bolette Søborg¹

During the 2024/25 influenza season, enhanced and standard-dose influenza vaccines were available for individuals aged 65 and older. Compared with the standard-dose quadrivalent influenza vaccine (QIV), the adjuvanted QIV was significantly more effective, with an overall vaccine effectiveness (VE) of 48% (95% CI: 42–52) vs 33% (95% CI: 24–41) when considering both non-hospitalised and hospitalised patients. The high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV. These findings support the inclusion of enhanced influenza vaccines in future vaccination programmes.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.12.2500174